Core Insights - Creative Medical Technology Holdings, Inc. announced positive mid-term follow-up data from its StemSpine® pilot study, which utilizes AlloStem™ cells for treating chronic lower back pain [1][2] Study Results - The pilot study showed a significant reduction in opioid dependency, with over 90% of patients reporting no opioid use for pain management three years post-procedure [2] - Pain scores decreased by 80%, and there was a greater than 60% improvement in Oswestry Disability Index scores [2] - Only one patient required reintervention at the three-year follow-up, and no serious adverse events were reported, indicating a favorable safety profile for the StemSpine® procedure [2] Technology Overview - StemSpine® is a patented, non-surgical, ultrasound-guided procedure that employs AlloStem™, an allogenic cell therapy developed by the company [3] - The patent for StemSpine® includes the use of both autologous and allogenic cells, enhancing its clinical applicability [3] Company Vision - The results highlight the safety and clinical efficacy of AlloStem™ in the StemSpine® procedure, promoting repair and improved vascularization in affected areas [4] - The company aims to provide innovative, non-surgical solutions for individuals suffering from chronic lower back pain [4] - The positive findings from the pilot study are expected to drive strong enrollment in the ongoing FDA-cleared Phase 1/2 ADAPT clinical trial for CELZ-201-DDT [4]
Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™